ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ISCO International Stem Cell Corporation (QB)

0.097
0.00 (0.00%)
May 10 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 1
Bid Price 0.09
Ask Price 0.109
News -
Day High

Low
0.046

52 Week Range

High
0.167

Day Low
Company Name Stock Ticker Symbol Market Type
International Stem Cell Corporation (QB) ISCO OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 0.097 11:08:28
Open Price Low Price High Price Close Price Prev Close
0.097 0.097
Trades Volume Avg Volume 52 Week Range
1 1 - 0.046 - 0.167
Last Trade Time Type Quantity Stock Price Currency
14:07:51 1 $ 0.09 USD

International Stem Cell Corporation (QB) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
800.44k 8.00M 2.19M 7.79M -131k -0.02 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

International Stem Cell (QB) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ISCO Message Board. Create One! See More Posts on ISCO Message Board See More Message Board Posts

Historical ISCO Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.0970.0970.090.09643874240.000.00%
1 Month0.1090.1090.06120.09678652,507-0.012-11.01%
3 Months0.100.120.05210.09161071,966-0.003-3.00%
6 Months0.110.150.0460.09472682,870-0.013-11.82%
1 Year0.1330.1670.0460.11637913,173-0.036-27.07%
3 Years0.4410.800.0460.3893055,596-0.344-78.00%
5 Years1.141.200.0460.51380445,637-1.04-91.49%

International Stem Cell (QB) Description

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial backgrounds, with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell?. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com).